Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

In Situ Vaccination With Flt3L, Radiation, and Poly-ICLC Combined With Pembrolizumab in Patients With Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, and Head and Neck Squamous Cell Carcinoma

Next Previous
Trial Profile

In Situ Vaccination With Flt3L, Radiation, and Poly-ICLC Combined With Pembrolizumab in Patients With Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, and Head and Neck Squamous Cell Carcinoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CDX 301 (Primary) ; Pembrolizumab (Primary) ; Poly ICLC (Primary)
  • Indications Advanced breast cancer; Chronic lymphocytic leukaemia; Head and neck cancer; Non-Hodgkin's lymphoma; Squamous cell cancer
  • Focus Adverse reactions

Most Recent Events

  • 21 Feb 2023 Planned End Date changed from 31 Mar 2026 to 1 Mar 2025.
  • 21 Feb 2023 Planned primary completion date changed from 31 Mar 2026 to 1 Mar 2025.
  • 18 Oct 2021 Planned End Date changed from 1 Jun 2023 to 31 Mar 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top